Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.45 |
| ▸ | DHFR | P00374 | 2/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27612525 | 0.79 | ADORA2A (0.63) | ADORA2AADORA1ADORA2BDHFRMAP4K4 | |
| SCHEMBL12137467 | 0.74 | ADORA1 (0.59) | ADORA2AADORA1ADORA2BXDHCLK4 | |
| SCHEMBL12137656 | 0.73 | ADORA2A (0.55) | ADORA2AADORA1DHFRATR | |
| SCHEMBL1358503 | 0.71 | ADORA2A (0.60) | ADORA2AADORA1ADORA2BDHFRXDH | |
| SCHEMBL12135604 | 0.71 | ADORA1 (0.60) | ADORA2AADORA1ADORA2BCLK4 | |
| SCHEMBL23173618 | 0.71 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BMAP4K4XDH | |
| SCHEMBL23162046 | 0.71 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BMAP4K4XDH | |
| SCHEMBL2323007 | 0.70 | ADORA2A (0.72) | ADORA2AADORA1ADORA2B | |
| SCHEMBL12135555 | 0.70 | ADORA2A (0.58) | ADORA2AADORA1ADORA2BDHFRATR | |
| SCHEMBL3365760 | 0.69 | ADORA2A (0.58) | ADORA2AADORA1ADORA2BDHFRMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806350-B2 | Prevention and/or treatment of CNS disorders | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11806350-B2 | Prevention and/or treatment of CNS disorders | ADORA2A, ADORA1, ADORA2B | ADORA2A 1/4885ADORA1 2/4885ADORA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.